Exagen (NASDAQ:XGN – Get Free Report) posted its quarterly earnings results on Tuesday. Exagen raised 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million, citing strong first-half execution and continued high-single-digit volume growth. Exagen Stock Up 37.8%XGN stock opened at $6.45 on Wednesday. Wall Street Zen upgraded Exagen from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Negative Sentiment: Exagen remains unprofitable, with a quarterly GAAP net loss of $3.2 million.